NeoGenomics Inc (NEO)vsThermo Fisher Scientific Inc (TMO)
NEO
NeoGenomics Inc
$17.32
-1.65%
HEALTHCARE · Cap: $2.27B
TMO
Thermo Fisher Scientific Inc
$609.82
+1.10%
HEALTHCARE · Cap: $225.48B
Smart Verdict
WallStSmart Research — data-driven comparison
Thermo Fisher Scientific Inc generates 5947% more annual revenue ($46.34B vs $766.29M). TMO leads profitability with a 15.0% profit margin vs -6.8%. TMO appears more attractively valued with a PEG of 1.80. TMO earns a higher WallStSmart Score of 60/100 (C+).
NEO
Hold48
out of 100
Grade: D+
TMO
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+78.2%
Fair Value
$52.45
Current Price
$17.32
$35.13 discount
Margin of Safety
-76.7%
Fair Value
$345.06
Current Price
$609.82
$264.76 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 130.6% YoY
Reasonable price relative to book value
Mega-cap, among the largest globally
Generating 1.7B in free cash flow
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
ROE of -12.0% — below average capital efficiency
Distress zone — elevated risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NEO
The strongest argument for NEO centers on EPS Growth, Price/Book. Revenue growth of 11.2% demonstrates continued momentum.
Bull Case : TMO
The strongest argument for TMO centers on Market Cap, Free Cash Flow. Revenue growth of 10.5% demonstrates continued momentum.
Bear Case : NEO
The primary concerns for NEO are PEG Ratio, Piotroski F-Score, Return on Equity.
Bear Case : TMO
The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
NEO profiles as a turnaround stock while TMO is a value play — different risk/reward profiles.
NEO carries more volatility with a beta of 1.75 — expect wider price swings.
NEO is growing revenue faster at 11.2% — sustainability is the question.
TMO generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
TMO scores higher overall (60/100 vs 48/100) and 10.5% revenue growth. NEO offers better value entry with a 78.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
NeoGenomics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company is headquartered in Fort Myers, Florida.
Thermo Fisher Scientific Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?